



Interplay between Nucleoid-Associated Proteins and Transcription Factors in Controlling Specialized Metabolism in *Streptomyces*

Xiafei Zhang,^{a,c} Sara N. Andres,^{b,c}  Marie A. Elliot^{a,c}

^aDepartment of Biology, McMaster University, Hamilton, Ontario, Canada

^bDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada

^cInstitute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada

ABSTRACT Lsr2 is a small nucleoid-associated protein found throughout the actinobacteria. Lsr2 functions similarly to the well-studied H-NS, in that it preferentially binds AT-rich sequences and represses gene expression. In *Streptomyces venezuelae*, Lsr2 represses the expression of many specialized metabolic clusters, including the chloramphenicol antibiotic biosynthetic gene cluster, and deleting *Lsr2* leads to significant up-regulation of chloramphenicol cluster expression. We show here that Lsr2 likely exerts its repressive effects on the chloramphenicol cluster by polymerizing along the chromosome and by bridging sites within and adjacent to the chloramphenicol cluster. CmlR is a known activator of the chloramphenicol cluster, but expression of its associated gene is not upregulated in an *Lsr2* mutant strain. We demonstrate that CmlR is essential for chloramphenicol production, and further reveal that CmlR functions to “countersilence” Lsr2’s repressive effects by recruiting RNA polymerase and enhancing transcription, with RNA polymerase effectively clearing bound Lsr2 from the chloramphenicol cluster DNA. Our results provide insight into the interplay between opposing regulatory proteins that govern antibiotic production in *S. venezuelae*, which could be exploited to maximize the production of bioactive natural products in other systems.

IMPORTANCE Specialized metabolic clusters in *Streptomyces* are the source of many clinically prescribed antibiotics. However, many clusters are not expressed in the laboratory due to repression by the nucleoid-associated protein Lsr2. Understanding how Lsr2 represses cluster expression, and how repression can be alleviated, is key to accessing the metabolic potential of these bacteria. Using the chloramphenicol biosynthetic cluster from *Streptomyces venezuelae* as a model, we explored the mechanistic basis underlying Lsr2-mediated repression, and activation by the pathway-specific regulator CmlR. Lsr2 polymerized along the chromosome and bridged binding sites located within and outside the cluster, promoting repression. Conversely, CmlR was essential for chloramphenicol production and further functioned to countersilence Lsr2 repression by recruiting RNA polymerase and promoting transcription, ultimately removing Lsr2 polymers from the chromosome. Manipulating the activity of both regulators led to a >130× increase in chloramphenicol levels, suggesting that combinatorial regulatory strategies can be powerful tools for maximizing natural product yields.

KEYWORDS *Streptomyces*, chloramphenicol, antibiotic, countersilencing, nucleoid-associated protein, Lsr2, activator, repressor

Streptomyces species are renowned for their complex life cycle and their ability to produce a wide range of medically useful specialized metabolites, including over two-thirds of the antibiotics in clinical use today. Genome sequencing has revealed that most *Streptomyces* spp. encode 25 to 50 specialized metabolic clusters (1–3);

Citation Zhang X, Andres SN, Elliot MA. 2021. Interplay between nucleoid-associated proteins and transcription factors in controlling specialized metabolism in *Streptomyces*. *mBio* 12:e01077–21. <https://doi.org/10.1128/mBio.01077-21>.

Editor Michael T. Laub, Massachusetts Institute of Technology

Copyright © 2021 Zhang et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Marie A. Elliot, melliot@mcmaster.ca.

Received 14 April 2021

Accepted 21 June 2021

Published 27 July 2021

however, the vast majority of their associated products have yet to be identified. Many of these clusters' genes are poorly transcribed, and consequently, their resulting products have never been detected under laboratory conditions (4–6). These “cryptic” and “silent” clusters have the potential to produce an impressive array of novel antibiotics (1, 7, 8), and activating their expression is one of the keys to facilitating new antibiotic discovery.

In *Streptomyces*, specialized metabolic clusters are controlled by multiple factors. These include cluster-situated regulators (encoded within their cognate biosynthetic gene clusters) that govern metabolite synthesis by directly binding promoter regions in their associated cluster. Pleiotropic regulators have also been implicated in antibiotic control; these are usually encoded elsewhere on the chromosome and affect the expression of multiple biosynthetic clusters (9). In recent years, nucleoid-associated proteins have also been found to influence the expression of specialized metabolic clusters (4, 10–12).

Historically, nucleoid-associated proteins function to promote chromosome organization; however, they can also impact activities like DNA replication, transcription, and chromosome segregation (13–15). H-NS (histone-like nucleoid-structuring protein) is one of the best-studied nucleoid-associated proteins. It is, however, found in only a subset of Gram-negative bacteria, where it preferentially binds and spreads along and/or bridges distal high-AT-content DNA, compacting the chromosome and/or silencing gene expression (14, 16–19). The resulting DNA filaments and/or DNA bridges formed by H-NS have the potential to affect gene expression by trapping RNA polymerase and repressing transcription, or by excluding RNA polymerase from promoter regions.

In the streptomycetes, H-NS-like proteins play important roles in regulating antibiotic production. The H-NS-equivalent protein in these bacteria is termed Lsr2, and it is conserved throughout the actinobacteria (15, 20). Like H-NS, Lsr2 is a global repressor that preferentially binds high AT-content DNA (4, 20, 21) and, based on work with the mycobacterial protein, is predicted to silence gene transcription by bridging or oligomerizing along the DNA (16, 17, 20). Deleting *Lsr2* in *Streptomyces venezuelae* leads to significantly upregulated gene expression in a majority of specialized metabolic biosynthetic clusters, including many otherwise cryptic clusters that are not expressed in a wild-type background (4). This suggests that Lsr2 functions to broadly repress specialized metabolism in *Streptomyces* species.

To better understand how Lsr2 repression is both exerted and alleviated in the streptomycetes, we focused our attention on the chloramphenicol biosynthetic cluster. Previous work revealed that loss of Lsr2 results in a dramatic increase in the expression of the chloramphenicol biosynthetic genes, and this effect seems to be a direct one, as an Lsr2 binding site was identified within the gene cluster (4) (Fig. 1). The chloramphenicol biosynthetic cluster comprises 16 genes (*sven0913* to *sven0928*), with *sven0913/cmlR* encoding a pathway-specific transcriptional activator (22). Here, we show that Lsr2 binding to the cluster-internal site, and to an upstream adjacent sequence, leads to Lsr2 polymerization along the DNA and can promote bridging between these two regions. This binding activity limits chloramphenicol production, presumably through the repression of cluster transcription. Lsr2 repression can be relieved through the action of CmlR, which functions as a countersilencer of Lsr2 activity and is essential for chloramphenicol production. CmlR appears to exert its activity not by competing with Lsr2 for binding but instead by promoting cluster transcription, where the action of RNA polymerase serves to clear Lsr2 from the DNA, alleviating cluster repression.

RESULTS

Antibiotic production is impacted by Lsr2 binding to sites adjacent to the chloramphenicol cluster. Lsr2 represses the expression of the majority of genes in the chloramphenicol biosynthetic cluster (4) (Fig. 1A). Intriguingly, the only Lsr2 binding site within the cluster was in the coding sequence of a gene (*sven0926*) located at the 3' end of the cluster (4) (Fig. 1A). We revisited our chromatin immunoprecipitation




FIG 1 Lsr2 binding sites and effect on transcription of the chloramphenicol biosynthetic cluster. (A) (Top) RNA-seq analysis of gene expression within and upstream of the chloramphenicol biosynthetic cluster in wild-type and *lsr2* mutant strains. Blue reads (and gene arrows) map to the reverse strand, and pink reads (and gene arrows) map to the forward strand; red arrow indicates *cmIR*, the pathway-specific regulator-encoding gene. (Bottom) ChIP-seq analysis of Lsr2 binding sites (using a FLAG-tagged Lsr2 variant), alongside a negative control (expressing untagged Lsr2). Red asterisks indicate statistically significant Lsr2 binding sites at *svn0904-svn0905* and within *svn0926*. (B) EMSAs probing Lsr2 binding to sites within and adjacent to the chloramphenicol biosynthetic cluster. Increasing concentrations of Lsr2 (0 to 500 nM) were combined with 1 nM labeled *svn0904-0905* (upstream/adjacent), *svn0926* (internal), or *svn3556* (negative control) probes. The results are representative of two independent biological replicates.

sequencing (ChIP-seq) data (4) and noted that there was a second Lsr2 binding site upstream of the cluster, spanning the genes *svn0904* and *svn0905* (referred to here as *svn0904-0905*), where *svn0904* is predicted to encode a solute binding transport lipoprotein and *svn0905* is predicted to encode a short-chain oxidoreductase (Fig. 1A). We first set out to validate Lsr2 binding to both internal and upstream sites using electrophoretic mobility shifts assays (EMSA). We found Lsr2 had a much higher affinity for *svn0904-0905* and *svn0926* probes than for a negative-control sequence (within *svn3556*, which was not bound by Lsr2 in our previous ChIP-seq experiments), confirming the specific binding of Lsr2 to these sites within and adjacent to the chloramphenicol cluster (Fig. 1B).

Given the functional similarity shared by Lsr2 and H-NS, we hypothesized that Lsr2 may exert its repressive effects in a manner analogous to that of H-NS, by polymerizing along the DNA and/or bridging distant DNA regions. We considered three mechanisms by which Lsr2 could repress transcription of the chloramphenicol cluster: (i) Lsr2 could bind within *svn0926* and polymerize along the chromosome, repressing expression of the flanking gene clusters; (ii) Lsr2 could bind to both *svn0904-0905* and *svn0926*




FIG 2 Deleting *sven0904-0905* from the chromosome increased chloramphenicol production. *sven0904-0905* were deleted in wild-type and $\Delta lsr2$ backgrounds, and LC-MS analyses were performed on the resulting strains after 2 days' growth in liquid culture, to quantify changes in chloramphenicol production relative to the wild type. Error bars represent standard deviations for three independent biological replicates. *, $P < 0.05$; ***, $P < 0.005$; ns, no significant difference.

sites and interact to bridge these sequences and alter the structure of the intervening DNA; or (iii) Lsr2 could both polymerize along the DNA and bridge these disparate sequences. We expected that if Lsr2 repressed transcription of the chloramphenicol cluster by polymerizing only from the *sven0926* binding site, then the *sven0904-0905* binding site would be dispensable for Lsr2 repression, and this region would have no effect on chloramphenicol production. If, however, Lsr2 repression was mediated by bridging these two sites (*sven0926* and *sven0904-0905*), or both polymerizing along the DNA and bridging these two regions, then deleting the upstream/cluster-adjacent binding site would relieve cluster repression and yield increased chloramphenicol levels relative to the wild-type strain.

To probe these different scenarios, we compared chloramphenicol production by wild-type and $\Delta lsr2$ strains, alongside a $\Delta 0904-0905$ mutant (where the deletion encompassed the entire coding regions of both *sven0904* and *sven0905*) and a double $\Delta lsr2 \Delta 0904-0905$ mutant strain using liquid chromatography–mass spectrometry (LC-MS). LC-MS analyses revealed that, relative to the wild type, deleting *sven0904-0905* led to a significant increase (~4-fold) in chloramphenicol production, while deleting both *lsr2* and *sven0904-0905* led to an ~13-fold increase in chloramphenicol production, which was similar to the production levels of the $\Delta lsr2$ mutant alone (~11-fold) (Fig. 2).

These results were consistent with a possible role for the *sven0904-0905* site in repressing chloramphenicol production through Lsr2 bridging between this site and the internal binding site. It was, however, formally possible that the products of these two upstream genes negatively influenced chloramphenicol production. To test this second possibility, we sought to complement the *sven0904-0905* mutant strains by cloning the operon containing wild-type *sven0904-0905* into the integrating plasmid vector pMS82. We reasoned that reintroducing these genes on a plasmid vector that integrated at an independent site in the chromosome should restore wild-type levels of chloramphenicol production if their products were important for antibiotic production, whereas no complementation of the mutant phenotype was expected if the locus position was critical for cluster repression. We introduced the complementation construct into the mutant strains alongside the empty plasmid as a control (in both mutants and the wild type) and assessed chloramphenicol production by these different strains. Complementation of the mutants ($\Delta 0904-0905$ and $\Delta lsr2 \Delta 0904-0905$) with the *sven0904-0906* operon failed to restore production levels to that of the empty plasmid-containing wild-type and $\Delta lsr2$ strains (Fig. S1). This suggested that the position of the *sven0904-0905* locus on the chromosome (and its associated Lsr2-binding site)—and not the function of the SVEN0904 and SVEN0905 gene products—may be important for controlling chloramphenicol production.

Lsr2 binding leads to polymerization along the DNA and bridging between sites upstream and within the chloramphenicol cluster. To explore the potential bridging capabilities of Lsr2, we employed atomic force microscopy (AFM). The two chloramphenicol cluster-associated Lsr2 binding sites are separated by 24 kb, which would be larger than ideal for use in AFM experiments. We initially opted to bring these two binding sites closer together, such that there was ~1 kb separating core binding sites (giving a total DNA fragment length of 2,919 bp). Lsr2 was then added, and the resulting products were visualized. If DNA bridging was the sole mechanism by which Lsr2 exerted its regulatory activity, we expected to see a loop formed between the Lsr2 binding sites at either end of the DNA fragment. However, we failed to detect any loop structures and instead observed only DNA molecules that had been coated and compacted by Lsr2, suggesting that Lsr2 could polymerize along the DNA under these *in vitro* conditions.

To better assess the bridging potential of Lsr2, we added an extra 1 kb of sequence between the two Lsr2 binding sites, to give a DNA fragment of ~4 kb. Using AFM, we compared the length of the DNA alone with that of DNA mixed with Lsr2. For the DNA-alone experiments, we needed to supplement the binding buffer with Ni²⁺ to facilitate DNA adherence to the mica slide used for the AFM experiments; Ni²⁺ was not added to the Lsr2-containing samples, as it disrupted DNA binding by Lsr2. For the DNA-alone controls, we observed linear DNA molecules (Fig. 3A and B), with an average length of 1,273.7 nm ($n = 71$) (Fig. 3B and C), consistent with the expected length of 1,200 nm for a 4-kb DNA molecule. In the presence of 250 nM Lsr2, looped molecules were identified alongside linear-appearing DNA-Lsr2 complexes ($n = 54$) (Fig. 3A and B). For the linear-appearing DNA-Lsr2 complexes, Lsr2 polymerization was apparent at one end of the DNA, but no obvious bridging was observed. In contrast, loop structures appeared to result from Lsr2 bridging the two distal regions. Notably, Lsr2 polymerization was also typically observed at each bridging site, where the loop appeared to have been “zipped up” (Fig. 3A). The lengths of both the looped and linear DNA-Lsr2 complexes were measured in the presence of 250 nM Lsr2, and the mean value was found to be 845.7 nm ($n = 54$) (Fig. 3B and C). To ensure that these changes in DNA structure and length stemmed from specific Lsr2 binding and oligomerization and not simply DNA folding back on itself, the height of the observed DNA-alone molecules and Lsr2-bound regions were measured; it was expected that Lsr2 binding to DNA would result in a minimum 3-fold increase in height. The mean values of the height of DNA alone and Lsr2-bound regions were 0.23 nm ($n = 71$) and 1.15 nm ($n = 36$), respectively (Fig. 3B and C). To further confirm that these DNA structures were the result of specific Lsr2 binding, equivalent experiments were performed using a 4.5-kb DNA fragment that lacked Lsr2 binding sites, based on our previous ChIP-seq analyses (4). As expected, DNA alone adopted a linear configuration. However, under the conditions used for Lsr2 binding, we consistently failed to detect any DNA, suggesting that Lsr2 was unable to specifically associate with this DNA fragment and tether the DNA to the slide (Fig. S2). In all, the AFM results suggested that Lsr2 could polymerize along the DNA and had the capacity to bridge disparately positioned sites (at least 4 kb apart) and polymerize toward each binding site. These collective actions may serve to downregulate chloramphenicol production by limiting RNA polymerase access/activity within the chloramphenicol biosynthetic cluster in *S. venezuelae*.

The pathway-specific regulator CmlR is essential for chloramphenicol production.

We next set out to understand how the cluster-situated regulator CmlR impacted chloramphenicol production. Our previous RNA sequencing results had revealed that the expression of most genes in the chloramphenicol biosynthetic cluster was significantly increased in the absence of Lsr2. A notable exception, however, was *cmlR* (*sven0913*), whose transcript levels were consistent in both wild-type and *lsr2* mutant strains (Fig. 1A). Consequently, we wondered whether CmlR might function simply to relieve Lsr2 repression and whether it was dispensable for cluster expression in the absence of Lsr2.

To test this hypothesis, we sought to determine the relative importance of CmlR in wild-type and *lsr2* mutant strains of *S. venezuelae*. We created strains in which *cmlR*




FIG 3 Lsr2 binds specific target sequences and can both form polymers along the DNA, and bridge binding sites. (A) (Top) AFM images of engineered (target) DNA molecules with two Lsr2 binding sites on either end. (Bottom) AFM images of 0.5 nM target DNA plus 250 nM Lsr2. White arrows indicate linear DNA molecules; orange arrows indicate looped structures. (B) Illustration of how length and height measurements of DNA alone and Lsr2-bound regions were taken. (C) (Left) Frequency distribution of length of Lsr2-bound/unbound DNA molecules. $n = 71$ for DNA only and 54 for DNA plus Lsr2. (Right) Frequency distribution of mean height of DNA alone (frequency axis on the left) and Lsr2-bound regions (frequency axis on the right). $n = 71$ for DNA alone and 36 for Lsr2-bound regions. Data are means and standard deviations, calculated from nonlinear Gaussian fit.

was deleted from the chromosome and in which it was overexpressed from a strong, constitutive (*ermE**) promoter on an integrating plasmid in both wild-type and *lsr2* mutant strains. We then tested chloramphenicol production levels in these different strains using LC-MS analyses. In these experiments, we found that deleting *lsr2* led to an ~8-fold increase in chloramphenicol production relative to the wild type and that deleting *cmIR* abolished chloramphenicol production in all strains. This suggested that CmlR was critical for chloramphenicol biosynthesis beyond simply relieving Lsr2 repression. Consistent with this observation, we found that overexpressing *cmIR* led to a massive increase in chloramphenicol production in wild-type strains (102-fold increase relative to plasmid-alone controls), while overexpressing CmlR in the absence of Lsr2 led to even higher chloramphenicol levels (134-fold increase) (Fig. 4). These results suggested that CmlR activity was essential for stimulating chloramphenicol production.

CmlR binds to a divergent promoter region in the chloramphenicol biosynthetic cluster. To begin to understand how CmlR exerted its regulatory effects within the chloramphenicol cluster, we examined its DNA binding capabilities. CmlR shares 44%




FIG 4 CmlR is required for chloramphenicol production in *S. venezuelae*. LC-MS analyses of changes in chloramphenicol production, relative to wild type, are plotted on a logarithmic graph. Gray, wild-type background; black, $\Delta lsr2$ background. N/D, not detected. Error bars represent standard deviations for two independent biological replicates.

amino acid sequence identity with StrR (22), which is the pathway-specific activator of the streptomycin biosynthetic gene cluster in *Streptomyces griseus* (23). The StrR target sequence is well-established (5'-GTTCTGACTGN₁₁CAGTCTGAAC-3') (23), and so we searched for similar sequences in the intergenic/promoter-containing regions of the chloramphenicol cluster. We identified a potential binding site for CmlR between the *sven0924* and *sven0925* promoters, upstream of the Lsr2 binding site within *sven0926* (Fig. 5A). To test whether CmlR specifically bound this sequence, we conducted EMSAs using the predicted binding site as a probe. We found that CmlR directly bound the promoter region with high affinity (Fig. 5B). We confirmed binding specificity using the promoter of a gene outside the chloramphenicol cluster (*sven5133*); there was no binding to this DNA fragment when equivalent concentrations of CmlR were used (Fig. 5B). This implied that CmlR specifically bound a site between the promoters driving the *sven0924*- and *sven0925*-associated operons.

CmlR alleviates Lsr2 repression within the chloramphenicol biosynthetic cluster.

Given the relative proximity of the CmlR and Lsr2 binding sites within the chloramphenicol cluster, and that CmlR overexpression appeared to overcome Lsr2-mediated repression of cluster expression, we wanted to determine whether CmlR could act to countersilence the repressive effects of Lsr2. To address this possibility, we tested whether overexpressing CmlR reduced Lsr2 binding within the chloramphenicol cluster. We introduced our Lsr2-FLAG-tagged expression construct into the *lsr2 cmIR* double-mutant strain and into an *lsr2* mutant strain overexpressing CmlR. Using ChIP to capture DNA sequences bound by Lsr2-FLAG, we then used quantitative PCR (qPCR) to compare the relative amount of target DNA (*sven0926*) bound by Lsr2 in strains lacking or overexpressing CmlR. To ensure that any CmlR-mediated effects were specific to Lsr2 binding within the chloramphenicol cluster, we also assessed Lsr2 binding to another validated Lsr2-binding site positioned outside the chloramphenicol cluster (*sven6264*), alongside negative-control sequences not bound by Lsr2 (based on previous ChIP experiments) (4).

Overexpressing CmlR reduced the levels of *sven0926* bound by Lsr2 by 40%, while deleting *cmIR* resulted in >100% increase in *sven0926* bound by Lsr2, relative to that bound by Lsr2 in the presence of wild-type levels of CmlR (Fig. 6). Overexpressing and deleting *cmIR* had no obvious effects on the abundance of either the external Lsr2 target *sven6264* or the negative-control sequence. Taken together, these findings indicated that CmlR activity could influence Lsr2 binding within the chloramphenicol biosynthetic cluster and, in doing so, had the potential to counter the repressive effects of Lsr2.




FIG 5 CmlR binds promoter regions within the chloramphenicol biosynthetic cluster. (A) (Top) Transcription start sites mapped for the *sven0924* and *sven0925* operons, as determined using differential RNA sequencing. (Middle) Schematic diagram showing the predicted CmlR binding site (red bar) within the divergent promoter region upstream of *sven0924* and *sven0925* and the Lsr2 binding site (gray bar) within *sven0926*. The predicted CmlR binding sequence is shown below, together with the analogous StrR binding sequence. Blue reads (and blue arrows) map to the reverse strand; orange reads (and orange arrows) map to the forward strand. (B) EMSA using 1 nM labeled *sven0924-0925* or *sven5133* (negative control) promoter regions as probes, together with increasing concentrations (0 to 150 nM) of purified CmlR. Results are representative of two independent mobility shift assays.

CmlR alleviates Lsr2 repression by enhancing transcription. How CmlR impacted Lsr2 binding was not immediately obvious. We hypothesized that CmlR functioned to recruit RNA polymerase and that the act of transcription disrupted the Lsr2 polymers/bridges, thus relieving Lsr2 repression (the CmlR binding site is immediately upstream of the *0925* promoter region) (Fig. 5). To test this possibility, we assessed whether inhibiting transcription affected Lsr2 binding, taking advantage of the fact that RNA polymerase (and correspondingly transcript elongation) could be inhibited by the antibiotic rifampicin (24, 25).

Using a strain expressing the FLAG-tagged Lsr2 protein and overexpressing CmlR, we performed ChIP experiments after a 10-min exposure to rifampicin. In parallel, ChIP experiments were done using an untreated control strain. We quantified and compared the levels of *sven0926* bound by Lsr2, both with and without rifampicin treatment, using qPCR. We knew that overexpressing CmlR reduced the levels of *sven0926* bound by Lsr2 (Fig. 7). Thus, we hypothesized that if CmlR alleviated Lsr2 binding and cluster repression by recruiting RNA polymerase and enhancing transcription, then inhibiting RNA polymerase activity would lead to increased Lsr2 binding to *sven0926*. We found that adding rifampicin to a CmlR-overexpressing strain led to a >500% increase in the amount of *sven0926* bound by Lsr2, relative to untreated controls. This suggested that CmlR relieved Lsr2 silencing by recruiting RNA polymerase, and the




FIG 6 CmlR levels affect Lsr2 binding. (A) ChIP-qPCR quantification of the relative abundance of *sven0926*, *sven6264* (Lsr2-binding site positioned outside the chloramphenicol cluster), and *sven4440* (negative control; not bound by Lsr2 in ChIP experiments) bound by Lsr2, in a strain with and without *cmlR* (black and gray bars, respectively). (B) qPCR analysis of ChIP DNA samples, quantifying the relative abundance of *sven0926*, *sven6264*, and *sven3885* (negative control; not bound by Lsr2 in ChIP experiments) in a strain with wild-type *cmlR* (black bars) versus a *cmlR* overexpression (O/E) strain (gray bars). For both panels A and B, error bars represent standard errors of the means, for technical triplicate and biological duplicate samples.

resulting increase in transcription served to remove Lsr2 polymers from the chromosome and/or disrupt Lsr2 bridges.

To further test the proposed mechanism of CmlR-mediated countersilencing of Lsr2 activity, we explored the effects of CmlR using a simplified system in which Lsr2 repression could be exerted only by polymerizing along the chromosome. We employed a transcriptional reporter system and fused two distinct promoter constructs to the *gusA* (β -glucuronidase-encoding) reporter gene (Fig. S3A). The first contained the CmlR binding site and promoter for *sven0925* and extended through to the downstream Lsr2 binding site (within *sven0926*). The second construct was the same, only with the CmlR binding site and *sven0925* promoter replaced with the constitutive *ermE** promoter. These two reporter constructs were introduced into wild-type and *Lsr2* mutant strains on an integrating plasmid vector, in parallel with a promoterless plasmid control. The active *ermE** promoter led to significantly increased β -glucuronidase activity in the wild-type background relative to the CmlR-controlled promoter, suggesting reduced Lsr2 repression. In contrast, in an $\Delta Lsr2$ background, β -glucuronidase activity did not differ significantly for the two reporter constructs, although we note that (for unknown reasons) the activity of the negative control was higher in this background (Fig. S3). Collectively, these results, when taken together with the results of the assays described above, suggested that Lsr2 repression could be alleviated by enhancing transcription.




FIG 7 Inhibiting transcription enhances Lsr2 binding to its *sven0926* target site. The relative abundance (fold change) of Lsr2-targeted *sven0926* in rifampicin-treated (and untreated) *cmlR* overexpression strains was compared using qPCR, with ChIP-DNA samples as the template. Error bars represent the standard errors of the means, for technical triplicates and biological duplicates. **, $P < 0.01$.

DISCUSSION

Lsr2 plays a pivotal role in repressing specialized metabolism in *Streptomyces* species (4), yet it is assumed that many of these specialized metabolic clusters must be expressed under specific circumstances. Here, we probed the mechanistic basis underlying Lsr2 repression of the chloramphenicol biosynthetic cluster in *S. venezuelae* and found that it appears to function by polymerizing along the chromosome and bridging sites within and adjacent to the biosynthetic cluster. We further explored how Lsr2 repression was alleviated and identified a key countersilencing function for the cluster-situated regulator CmlR, which enhances transcription, leading to RNA polymerase effectively clearing Lsr2 from the chromosome (Fig. 8).

Unlike most transcription factors, nucleoid-associated proteins typically bind DNA with low affinity and/or specificity, and this is consistent with our observations, where we found that CmlR bound its target sequences with far greater affinity than Lsr2. To date, the countersilencing of nucleoid-associated protein-mediated repression has been best studied for H-NS. Three main mechanisms having been reported: (i) regulatory proteins remodel the DNA and disrupt the H-NS-DNA complex, facilitating transcription initiation by RNA polymerase (e.g., VirB alleviates H-NS repression at promoters of virulence genes in *Shigella flexneri*) (26, 27); (ii) DNA-binding proteins compete with H-NS for binding to a given site and in doing so relieve H-NS repression (e.g., in *Vibrio harveyi*, the LuxR transcription factor relieves H-NS repression of bioluminescence by competing with H-NS for binding to the promoter of quorum sensing genes) (28); and (iii) transcribing RNA polymerase derepresses H-NS by remodeling or disrupting the H-NS complex, ultimately enhancing transcription (e.g., in *Salmonella*, PhoP reduces H-NS binding to horizontally acquired genes by competing with H-NS for binding, and enhancing transcription by recruiting RNA polymerase [29, 30]).

Counter-silencing of Lsr2 in *Mycobacterium tuberculosis* has been previously described in relation to iron metabolism (31). The expression of *bfr*, encoding a bacterioferritin, is governed both by Lsr2 and the iron-dependent transcriptional regulator IdeR. Lsr2 binds directly to the promoter of *bfrB*, thereby preventing its transcription. Under iron-replete conditions, IdeR is activated by iron binding and alleviates Lsr2 repression by directly associating with the *bfrB* promoter (31). However, it is not clear whether relief of Lsr2 repression is accomplished through direct competition between IdeR and Lsr2 for binding or by IdeR enhancing transcription levels, as appears to be the case for CmlR and Lsr2 in *S. venezuelae* (31). Countersilencing has also been explored for the *Corynebacterium* homologue known as CgpS, using synthetic systems (32). These experiments revealed that countersilencing of Lsr2 bound to a single site/region (i.e., not bridging different sequences) was most effectively achieved through




FIG 8 Proposed model for Lsr2 repression and CmlR countersilencing in chloramphenicol cluster expression. (A) In the wild type, Lsr2 represses expression of the chloramphenicol cluster by polymerizing along the chromosome and bridging sites between *svn0926* and *svn0904-0905*. Low levels of CmlR bind the divergently expressed promoter region between *svn0924* and *svn0925* and promote baseline cluster expression and low-level production of chloramphenicol. (B) Deleting *cmlR* leads to a complete loss of cluster expression and chloramphenicol production. (C) In the *lsr2* mutant, the repressing Lsr2 polymers and bridges are absent, allowing CmlR to recruit more RNA polymerase to the divergent promoter region, leading to higher cluster expression and more chloramphenicol production. (D) Overexpressed CmlR cooperatively binds the promoter, and its strong recruitment of RNA polymerase, and the associated increase in transcription, serves to remove Lsr2 from the chromosome and neutralizes its repressive effect, leading to high-level chloramphenicol production.

competition for binding by transcription factors at the CgpS nucleation site, presumably serving to limit polymerization along the DNA (32). While it is possible that CmlR has a minor role in limiting the bounds of polymerization, our data suggest that its major function is to promote transcription and in doing so to facilitate Lsr2 removal from the chromosome. What controls the expression of *cmlR* remains to be determined, as its expression is unaffected by Lsr2 activity.

Previous work has revealed that Lsr2 binding sites are found in the majority of biosynthetic gene clusters in *S. venezuelae*, including the chloramphenicol cluster (4). Our data support a model in which Lsr2 employs both an internal and external binding site to downregulate the expression of the chloramphenicol biosynthetic genes (and production of chloramphenicol). We were curious whether such a binding configuration was associated with other Lsr2-targeted clusters. In examining the data of Gehrke et al. (4), we noted that nine clusters contained more than one Lsr2 binding site, and most of these clusters (7/9) exhibited altered transcription profiles in an *lsr2* mutant. Of the clusters which are associated with a single Lsr2 binding site and which also have altered transcription patterns (6 clusters), all but one have a cluster-adjacent Lsr2 binding site (within 12 genes upstream or downstream), and most of these were oriented such that the binding sites spanned the majority of the cluster (i.e., the external binding site was usually on the side opposite the internal binding site). This suggests that the model we propose for control of the chloramphenicol cluster (polymerization and bridging) may be broadly employed throughout *S. venezuelae* for repression of specialized metabolism. Whether any regulators encoded within these clusters play roles equivalent to that of CmlR in the chloramphenicol cluster, in helping to relieve Lsr2 repression, remains to be seen.

Understanding the different ways in which Lsr2 can exert its repressive effects is central to our ability to effectively manipulate its activity and, in doing so, gain access to the vast cryptic metabolic repertoire of the streptomycetes. Countersilencing by cluster-situated activators likely represents one of many approaches employed by

TABLE 1 Strains used in this study

Strains	Genotype, characteristics, or use	Reference or source
<i>Streptomyces venezuelae</i>		
ATCC 10712	Wild type	
E327	<i>S. venezuelae</i> <i>lsr2::aac(3)IV</i>	4
E327A	<i>S. venezuelae</i> Δ <i>lsr2</i>	4
E332	<i>S. venezuelae</i> <i>cmlR::aac(3)IV</i>	This work
E333	<i>S. venezuelae</i> Δ <i>lsr2</i> <i>cmlR::aac(3)IV</i>	This work
E334	<i>S. venezuelae</i> <i>sven0904_0905::aac(3)IV</i>	This work
E335	<i>S. venezuelae</i> Δ <i>lsr2</i> <i>sven0904_0905::aac(3)IV</i>	This work
E336	<i>S. venezuelae</i> Δ <i>lsr2</i> with pIJ82 carrying wild-type <i>lsr2</i>	4
E337	<i>S. venezuelae</i> Δ <i>lsr2</i> with pIJ10706 carrying <i>lsr2-3</i> × <i>Gly-3</i> × <i>FLAG</i>	4
<i>Escherichia coli</i>		
DH5 α	Routine cloning	48
SE DH5 α	Highly competent (Subcloning Efficiency) DH5 α cells	Invitrogen
ET12567	<i>dam dcm hsdS cat tet</i> ; carries <i>trans</i> -mobilizing plasmid pUZ8002	39
Rosetta 2	Protein overexpression host with pRARE2, which supplies "rare" tRNAs	Novagen

Streptomyces spp. to modulate the effects of Lsr2. It will be interesting to determine whether the activity of Lsr2 in the streptomycetes is impacted by environmental factors like H-NS (e.g., temperature) (19), alternative binding partners like H-NS (e.g., StpA) (33) and Lsr2 in *M. tuberculosis* (e.g., HU) (34), or posttranslational modification (35, 36).

MATERIALS AND METHODS

Bacterial strains and culture conditions. *S. venezuelae* strains were grown at 30°C on MYM (maltose, yeast extract, malt extract) agar, or in liquid MYM medium. *Escherichia coli* strains were grown at 37°C on or in LB (lysogeny broth) medium (37). *Streptomyces* and *E. coli* strains that were constructed and used are summarized in Table 1. Where appropriate, antibiotic selection was used for plasmid maintenance or for screening/selecting during mutant strain construction. For assessing the importance of transcription for Lsr2 countersilencing, *S. venezuelae* liquid cultures were grown for 16 h, after which they were exposed to the RNA polymerase-targeting antibiotic rifampicin (500 μ g/ml) for 10 min.

Mutant/overexpression strain construction. In-frame deletions of *cmlR* and *sven0904-0905* were created using ReDirect technology (38). The coding sequence of *cmlR* and the region encompassing *sven0904-0905* in cosmid 4P22 was replaced with the *aac(3)IV-oriT* apramycin resistance cassette (Table S1). Mutant cosmids 4P22 Δ *cmlR::aac(3)IV-oriT* and 4P22 Δ *0904_0905::aac(3)IV-oriT* were confirmed by PCR before being introduced into the nonmethylating *E. coli* strain ET12567/pUZ8002 (39, 40) and conjugated into wild-type *S. venezuelae* or *lsr2* mutant strains. The sequences of primers used to create the disruption cassettes and to check the integrity of the disrupted cosmids and chromosomal mutations can be found in Table S1.

The *cmlR* overexpression plasmids were made by cloning the *cmlR* gene and 216 bp of its downstream sequence under the control of the constitutive, highly active *ermE** promoter in the integrating plasmids pIJ82 and pRT801. For pIJ82, *cmlR* was amplified using primers *cmlR*fwd1 and *cmlR*rev1 (Table S1), digested with BamHI, and cloned into the BamHI site of pIJ82 (Table 2). For pRT801, *cmlR* was amplified using primers *cmlR*fwd2 and *cmlR*rev2 (Table S1) before being digested with SpeI and cloned into the same site in pRT801 (Table 2). *cmlR* presence and orientation in both plasmids were checked by PCR using vector- and insert-specific primers (Table S1), and construct integrity was confirmed by sequencing. The resulting plasmids, alongside empty plasmid controls, were introduced into *S. venezuelae* strains via conjugation from *E. coli* strain ET12567/pUZ8002 (Table 1). Strains used for chromatin immunoprecipitation (ChIP) were generated by introducing the pRT801-based *cmlR* overexpression construct into *lsr2* mutant strains complemented with either *lsr2* or *lsr2-3*×*FLAG* on the integrating plasmid vector pIJ82 and pIJ10706, respectively (Table 1) (4).

Δ 0904-0905 mutants were complemented by cloning the entire *sven0904-0906* operon, including 513 bp upstream and 123 bp downstream sequences (using primers 0904_0906CF and 0904_0906CR [Table S1]), into the EcoRV-digested integrating plasmid vector pMS82. The resulting construct was sequenced before being introduced into *E. coli* strain ET12567/pUZ8002, alongside empty vector control plasmids, and conjugated into *S. venezuelae* Δ 0904-0905 and Δ *lsr2* Δ 0904-0905 strains.

Protein overexpression and purification and EMSAs. Lsr2 overexpression and purification was performed as described previously (4). To overexpress CmlR in *E. coli*, the *cmlR* coding sequence was PCR amplified using primers *cmlR* O/E fwd and *cmlR* O/E rev (Table S1). The resulting product was digested with NdeI and BamHI before being ligated into the equivalently digested pET15b vector (Table 2). After sequencing to confirm construct integrity, the resulting plasmid was introduced into *E. coli* Rosetta 2 cells (Table 1). The resulting 6×His-CmlR overexpression strain was grown at 37°C until it reached an optical density at 600 nm (OD₆₀₀) of 0.6, at which point 0.5 mM isopropyl- β -D-1-thiogalactopyranoside (IPTG) was added. Cells were then grown at 30°C for 3.5 h before being collected and lysed. The

TABLE 2 Plasmids and cosmid used in this study

Cosmid or plasmid	Description	Reference or source
Cosmid 4P22	<i>S. venezuelae</i> cosmid carrying <i>cmlR</i> and <i>sven0904_0905</i>	Gift from M. Buttner
pJ82	Integrative cloning vector; <i>ori</i> pUC18 <i>hyg oriT</i> RK2 <i>int</i> Φ C31 <i>attP</i> Φ C31	Gift from H. Kieser
pRT801	Integrative cloning vector; <i>ori</i> pUC18 <i>apra oriT</i> RK2 <i>int</i> Φ BT1 <i>attP</i> Φ BT1	49
pMS82	Integrative cloning vector: <i>hyg oriT int</i> Φ BT1 <i>attP</i> Φ BT1	49
pGUS	Integrative <i>Streptomyces</i> -specific reporter vector for transcriptional fusions with the <i>gusA</i> gene	47
pGUS- <i>PermE</i> *	Strong <i>Streptomyces</i> promoter, <i>PermE</i> *, upstream of <i>gusA</i>	R. J. St-Onge (unpublished)
pBluescript II KS(+)	Standard cloning vector	Stratagene
pET15b	Overexpression of N-terminally His ₆ -tagged proteins	Novagen
pMC122	<i>cmlR</i> cloned downstream of <i>ermE</i> * in pJ82	This study
pMC123	<i>cmlR</i> cloned downstream of <i>ermE</i> * in pRT801	This study
pMC124	pET15b carrying <i>cmlR</i> for overexpression with an N-terminal His ₆ tag	This study
pMC125	pMS82 carrying <i>sven0904_0906</i>	This study
pMC126	pGUS carrying <i>sven0925_0926</i>	This study
pMC127	pGUS- <i>PermE</i> * carrying promoterless <i>sven0925_0926</i>	This study

overexpressed protein was purified from the cell extract using nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography and was washed using increasing concentrations of imidazole (50 mM to 250 mM) before being eluted using 500 mM imidazole. Finally, purified 6×His-CmlR was exchanged to storage buffer suitable for both EMSAs and freezing at -80°C (50 mM NaH_2PO_4 , 300 mM NaCl, and 10% glycerol, pH 8).

To test Lsr2-binding specificity, EMSAs were performed using 100- to 222-bp probes amplified by PCR and 5' end labeled with [γ - ^{32}P]dATP (Table S1). Lsr2 (0 to 500 nM) was combined with 1 nM probe and binding buffer (10 mM Tris [pH 7.8], 5 mM MgCl_2 , 60 mM KCl, and 10% glycerol) in 20- μl reaction volumes. Reaction mixtures were incubated at room temperature for 10 min, followed by 30 min on ice. Any resulting complexes were then separated on a 10% native polyacrylamide gel.

To test CmlR binding to the divergent promoter region between *sven0924* and *sven0925*, a 270-bp probe encompassing the predicted binding site (amplified using primers CmlR binding F and CmlR binding R [Table S1]) was used for EMSAs. CmlR (0 to 150 nM) was combined with 1 nM probe and binding buffer, as described above for Lsr2. Reaction mixtures were incubated at 30°C for 30 min before being separated on a 10% native polyacrylamide gel. EMSA gels were exposed to a phosphor screen for 3 h before being imaged using a phosphorimager.

Atomic force microscopy. Lsr2 binding sites, plus considerable flanking sequences, were amplified using AFM0905F and AFM0905R (Table S1) for *sven0904-0905* (1,612-bp product) and AFM0926F and AFM0926R (Table S1) for *sven0926* (2,441-bp product). The resulting DNA products were cloned into pBluescript II KS(+) at the EcoRV and SmaI sites, respectively. The orientation of each fragment was assessed by PCR using vector- and insert-specific oligonucleotides (Table S1) and confirmed by sequencing. The resulting hybrid product was then amplified with AFM0905R and AFM0926R (Table S1), for use in atomic force microscopy (AFM). Lsr2 was overexpressed and purified as described above. Negative-control DNA (sequences not bound by Lsr2 *in vivo*) was amplified from *S. venezuelae* genomic DNA using primers 7031F and 7031R (Table S1). The DNA-alone samples were prepared in 20- μl reaction volumes and contained 0.5 nM target DNA, 10 mM Tris-HCl (pH 7.6), 5 mM NiCl_2 , 40 mM HEPES, while the Lsr2+DNA samples, also prepared in 20- μl reaction volumes, contained 0.5 nM target DNA, 250 nM Lsr2, 10 mM Tris (pH 7.8), 5 mM MgCl_2 , 60 mM KCl, and 10% glycerol. Different buffer conditions were used for DNA alone and Lsr2+DNA because Ni^{2+} was needed for DNA binding to the mica slide; however, it was not compatible with Lsr2 binding, so was excluded from protein-containing reactions. Reaction mixtures were incubated at room temperature for 10 min, followed by 30 min on ice. The DNA or DNA/Lsr2 was then deposited onto freshly cleaved mica surfaces (Ted Pella, Inc.) and rinsed with 1 ml nuclease-free water. Water was removed by blotting with filter paper, after which the mica surface was dried using a stream of nitrogen. AFM was performed as described by Cannavo et al. (41). Images (2 by 2 μm) were captured in air using a Bruker Bioscope Catalyst atomic force microscope with ScanAsyst Air probes. Observed molecules were processed (through plane fit and flattening) and analyzed using Image Metrics version 1.44 (42, 43).

ChIP-qPCR. ChIP-qPCR was performed as described previously (4). Strains were inoculated in 10 ml of liquid MYM medium and grown overnight, before being subcultured in duplicate in 50 ml of MYM medium. After incubation for 18 h, formaldehyde was added to a final concentration of 1% (vol/vol) to cross-link protein to DNA. The cultures were then incubated for a further 30 min, before glycine was added to a final concentration of 125 mM. Immunoprecipitation of Lsr2-FLAG (or, as a negative control, untagged Lsr2) was performed as described previously (44) using the FLAG M2 antibody (Sigma).

To quantify the relative abundance of target genes of interest in the ChIP DNA samples, 20 μl qPCR mixtures were prepared using the LUNA Universal qPCR master mix (New England Biolabs), together with 2.5 μl of ChIP DNA (1:10) as the template. Primer pairs used to amplify the different target DNA sequences are summarized in Table S1. Target gene levels in ChIP DNA were calculated using data analysis for real-time PCR (DART-PCR) (45) and were normalized to the abundance of the relevant target gene in total DNA as described previously (46).

Secondary metabolite extraction and LC-MS analysis. Metabolite extraction and LC-MS analyses were performed as described previously (4), with minor modifications. Strains were grown in triplicate in 30 ml liquid MYM medium at 30°C for 2 days. Cultures were lyophilized and the resulting lyophiles were resuspended in 10 ml methanol and shaken overnight on a rotary shaker at 4°C. After centrifugation to remove particulate matter, the soluble samples were concentrated using a centrifugal vacuum evaporator (Genevac). The resulting products were then redissolved in 50% methanol and centrifuged again to remove residual particulate matter. The resulting soluble extracts were used for LC-MS analyses.

The extracts were analyzed using an Agilent 1200 LC coupled to a Bruker microTOF II (electrospray ionization-MS [ESI-MS]). One microliter of the injected extracts was separated on a Zorbax Eclipse XDB C₁₈ column (100 mm by 2.1 mm by 3.5 mm) at a flow rate of 0.4 ml/min for 22 min. Extracted metabolite separation was achieved using a gradient of 0 to 11 min from 95% to 5% A, 11 to 12 min isocratic 5% A, a gradient of 12 to 21 min from 5% to 95% A, and 21 to 22 min isocratic 95% A, where A is water with 0.1% formic acid and B is acetonitrile with 0.1% formic acid. Chloramphenicol was detected using the negative ionization mode, at 321 *m/z*.

β-Glucuronidase (Gus) reporter assays. To test how promoter activity affected Lsr2 binding, sequences encompassing the CmlR binding site and *sven0925* promoter, through to the Lsr2 binding site in *sven0926*, were amplified and cloned into the KpnI and SpeI sites of pGUS (47) using primers 0925_26 pGUS F and 0925_26 pGUS R (Table S1). To replace the native promoter of *sven0925* with the constitutive *ermE** promoter, the *ermE** promoter was amplified from plasmid pGUS-*PermE** (Table 2) using primers ermEF-X and ermER-K (Table S1) and cloned into the XbaI and KpnI sites of pGUS. Into the downstream SpeI site was then cloned the promoterless *sven0925_0926* fragment amplified using 0925_26 pGUS-E*F and 0925_26 pGUS R (Table S1). The resulting constructs were confirmed by sequencing and were introduced into *S. venezuelae* wild-type and *Lsr2* mutant strains by conjugation, alongside a promoterless pGUS control plasmid.

The resulting pGUS-containing strains were inoculated into 10 ml MYM medium and grown at 30°C for 18 h, after which 1 ml of culture was removed and assayed for β-glucuronidase activity. Cell pellets were resuspended in lysis buffer (50 mM phosphate buffer [pH 7.0], 0.27% [vol/vol] β-mercaptoethanol, 0.1% [vol/vol] Triton X-100, 1 mg/ml lysozyme) and incubated at 37°C for 30 min. After incubation, the cell lysate was centrifuged, and the resulting supernatant was used in the assay. Fifty microliters of supernatant was added to a 200-μl (total) reaction mixture, together with the *p*-nitrophenyl-β-D-glucuronide substrate (PNPG; Sigma-Aldrich) at a concentration of 600 μg/ml. Gus activity was determined by measuring the reaction absorbance at 420 nm and normalizing to the OD₆₀₀ of cultures.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, PDF file, 0.8 MB.

FIG S2, PDF file, 0.6 MB.

FIG S3, PDF file, 0.9 MB.

TABLE S1, XLSX file, 0.01 MB.

ACKNOWLEDGMENTS

We thank Lucas Koehlin for atomic force microscopy assistance, Mark Buttner and Matt Bush for their sharing of transcription start site data, and members of the Elliot and Andres labs for helpful comments and suggestions.

This work was supported by a Canadian Institute of Health Research (CIHR) Project grant to M.A.E. (PJT-162340), and a Natural Sciences and Engineering Research Council (NSERC) Discovery grant to S.N.A. X.Z. was supported by an International Ontario Graduate Scholarship.

REFERENCES

- Lee N, Hwang S, Kim J, Cho S, Palsson B, Cho BK. 2020. Mini review: Genome mining approaches for the identification of secondary metabolite biosynthetic gene clusters in *Streptomyces*. *Comput Struct Biotechnol J* 18:1548–1556. <https://doi.org/10.1016/j.csbj.2020.06.024>.
- Belknap KC, Park CJ, Barth BM, Andam CP. 2020. Genome mining of biosynthetic and chemotherapeutic gene clusters in *Streptomyces* bacteria. *Sci Rep* 10:2003. <https://doi.org/10.1038/s41598-020-58904-9>.
- Doroghazi JR, Metcalf WW. 2013. Comparative genomics of actinomycetes with a focus on natural product biosynthetic genes. *BMC Genomics* 14:611. <https://doi.org/10.1186/1471-2164-14-611>.
- Gehrke EJ, Zhang X, Pimentel-Elardo SM, Johnson AR, Rees CA, Jones SE, Hindra Gehrke SS, Turvey S, Boursalie S, Hill JE, Carlson EE, Nodwell JR, Elliot MA. 2019. Silencing cryptic specialized metabolism in *Streptomyces* by the nucleoid-associated protein Lsr2. *Elife* 8:e47791. <https://doi.org/10.7554/eLife.47691>.
- Yoon V, Nodwell JR. 2014. Activating secondary metabolism with stress and chemicals. *J Ind Microbiol Biotechnol* 41:415–424. <https://doi.org/10.1007/s10295-013-1387-y>.
- Zhang X, Hindra, Elliot MA. 2019. Unlocking the trove of metabolic treasures: activating silent biosynthetic gene clusters in bacteria and fungi. *Curr Opin Microbiol* 51:9–15. <https://doi.org/10.1016/j.mib.2019.03.003>.
- Xu F, Nazari B, Moon K, Bushin LB, Seyedsayamdost MR. 2017. Discovery of a cryptic antifungal compound from *Streptomyces albus* J1074 using high-throughput elicitor screens. *J Am Chem Soc* 139:9203–9212. <https://doi.org/10.1021/jacs.7b02716>.
- Hoshino S, Onaka H, Abe I. 2019. Activation of silent biosynthetic pathways and discovery of novel secondary metabolites in actinomycetes by co-culture with mycolic acid-containing bacteria. *J Ind Microbiol Biotechnol* 46:363–374. <https://doi.org/10.1007/s10295-018-2100-y>.

9. Bibb MJ. 2005. Regulation of secondary metabolism in *Streptomyces*. *Curr Opin Microbiol* 8:208–215. <https://doi.org/10.1016/j.mib.2005.02.016>.
10. Gao C, Hindra Mulder D, Yin C, Elliot MA. 2012. Crp is a global regulator of antibiotic production in *Streptomyces*. *mBio* 3:e00407-12. <https://doi.org/10.1128/mBio.00407-12>.
11. Swiercz JP, Nanji T, Gloyd M, Guarne A, Elliot MA. 2013. A novel nucleoid-associated protein specific to the actinobacteria. *Nucleic Acids Res* 41:4171–4184. <https://doi.org/10.1093/nar/gkt095>.
12. Yang YH, Song E, Willems J, Park SH, Kim WS, Kim EJ, Lee BR, Kim JN, van Wezel GP, Kim BG. 2012. A novel function of *Streptomyces* integration host factor (slHF) in the control of antibiotic production and sporulation in *Streptomyces coelicolor*. *Antonie Van Leeuwenhoek* 101:479–492. <https://doi.org/10.1007/s10482-011-9657-z>.
13. Badrinarayanan A, Le TB, Laub MT. 2015. Bacterial chromosome organization and segregation. *Annu Rev Cell Dev Biol* 31:171–199. <https://doi.org/10.1146/annurev-cellbio-100814-125211>.
14. Song D, Loparo JJ. 2015. Building bridges within the bacterial chromosome. *Trends Genet* 31:164–173. <https://doi.org/10.1016/j.tig.2015.01.003>.
15. Szafran MJ, Jakimowicz D, Elliot MA. 2020. Compaction and control—the role of chromosome-organizing proteins in *Streptomyces*. *FEMS Microbiol Rev* 44:725–739. <https://doi.org/10.1093/femsre/fuaa028>.
16. van der Valk RA, Vreede J, Qin L, Moolenaar GF, Hofmann A, Goosen N, Dame RT. 2017. Mechanism of environmentally driven conformational changes that modulate H-NS DNA-bridging activity. *Elife* 6:e17369. <https://doi.org/10.7554/eLife.27369>.
17. Qin L, Bdira FB, Sterckx YGJ, Volkov AN, Vreede J, Giachin G, van Schaik P, Ubbink M, Dame RT. 2020. Structural basis for osmotic regulation of the DNA binding properties of H-NS proteins. *Nucleic Acids Res* 48:2156–2172. <https://doi.org/10.1093/nar/gkz1226>.
18. Qin L, Erkelens AM, Ben Bdira F, Dame RT. 2019. The architects of bacterial DNA bridges: a structurally and functionally conserved family of proteins. *Open Biol* 9:190223. <https://doi.org/10.1098/rsob.190223>.
19. Shahul Hameed UF, Liao C, Radhakrishnan AK, Huser F, Aljedani SS, Zhao X, Momin AA, Melo FA, Guo X, Brooks C, Li Y, Cui X, Gao X, Ladbury JE, Jaremko L, Jaremko M, Li J, Arold ST. 2019. H-NS uses an autoinhibitory conformational switch for environment-controlled gene silencing. *Nucleic Acids Res* 47:2666–2680. <https://doi.org/10.1093/nar/gky1299>.
20. Gordon BR, Li Y, Wang L, Sintsova A, van Bakel H, Tian S, Navarre WW, Xia B, Liu J. 2010. Lsr2 is a nucleoid-associated protein that targets AT-rich sequences and virulence genes in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A* 107:5154–5159. <https://doi.org/10.1073/pnas.0913551107>.
21. Chen JM, Ren H, Shaw JE, Wang YJ, Li M, Leung AS, Tran V, Berbenetz NM, Kocincova D, Yip CM, Reyat JM, Liu J. 2008. Lsr2 of *Mycobacterium tuberculosis* is a DNA-bridging protein. *Nucleic Acids Res* 36:2123–2135. <https://doi.org/10.1093/nar/gkm1162>.
22. Fernandez-Martinez LT, Borsetto C, Gomez-Escribano JP, Bibb MJ, Al-Bassam MM, Chandra G, Bibb MJ. 2014. New insights into chloramphenicol biosynthesis in *Streptomyces venezuelae* ATCC 10712. *Antimicrob Agents Chemother* 58:7441–7450. <https://doi.org/10.1128/AAC.04272-14>.
23. Tomono A, Tsai Y, Yamazaki H, Ohnishi Y, Horinouchi S. 2005. Transcriptional control by A-factor of strR, the pathway-specific transcriptional activator for streptomycin biosynthesis in *Streptomyces griseus*. *J Bacteriol* 187:5595–5604. <https://doi.org/10.1128/JB.187.16.5595-5604.2005>.
24. Campbell EA, Korzhova N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. 2001. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. *Cell* 104:901–912. [https://doi.org/10.1016/s0092-8674\(01\)00286-0](https://doi.org/10.1016/s0092-8674(01)00286-0).
25. Chen H, Shiroguchi K, Ge H, Xie XS. 2015. Genome-wide study of mRNA degradation and transcript elongation in *Escherichia coli*. *Mol Syst Biol* 11:781. <https://doi.org/10.15252/msb.20145794>.
26. Stoebel DM, Free A, Dorman CJ. 2008. Anti-silencing: overcoming H-NS-mediated repression of transcription in Gram-negative enteric bacteria. *Microbiology (Reading)* 154:2533–2545. <https://doi.org/10.1099/mic.0.2008/020693-0>.
27. Beloin C, Dorman CJ. 2003. An extended role for the nucleoid structuring protein H-NS in the virulence gene regulatory cascade of *Shigella flexneri*. *Mol Microbiol* 47:825–838. <https://doi.org/10.1046/j.1365-2958.2003.03347.x>.
28. Chaparian RR, Tran MLN, Miller Conrad LC, Rusch DB, van Kessel JC. 2020. Global H-NS counter-silencing by LuxR activates quorum sensing gene expression. *Nucleic Acids Res* 48:171–183. <https://doi.org/10.1093/nar/gkz1089>.
29. Rangarajan AA, Schnetz K. 2018. Interference of transcription across H-NS binding sites and repression by H-NS. *Mol Microbiol* 108:226–239. <https://doi.org/10.1111/mmi.13926>.
30. Choi J, Groisman EA. 2020. *Salmonella* expresses foreign genes during infection by degrading their silencer. *Proc Natl Acad Sci U S A* 117:8074–8082. <https://doi.org/10.1073/pnas.1912808117>.
31. Kurthkoti K, Tare P, Paitchowdhury R, Gowthami VN, Garcia MJ, Colangeli R, Chatterji D, Nagaraja V, Rodriguez GM. 2015. The mycobacterial iron-dependent regulator IdeR induces ferritin (bfrB) by alleviating Lsr2 repression. *Mol Microbiol* 98:864–877. <https://doi.org/10.1111/mmi.13166>.
32. Wiechert J, Filipchuk A, Hunnefeld M, Gatgens C, Brehm J, Heermann R, Frunzke J. 2020. Deciphering the rules underlying xenogeneic silencing and counter-silencing of Lsr2-like proteins using CgpS of *Corynebacterium glutamicum* as a model. *mBio* 11:e02273-19. <https://doi.org/10.1128/mBio.02273-19>.
33. Muller CM, Dobrindt U, Nagy G, Emody L, Uhlin BE, Hacker J. 2006. Role of histone-like proteins H-NS and StpA in expression of virulence determinants of uropathogenic *Escherichia coli*. *J Bacteriol* 188:5428–5438. <https://doi.org/10.1128/JB.01956-05>.
34. Datta C, Jha RK, Ahmed W, Ganguly S, Ghosh S, Nagaraja V. 2019. Physical and functional interaction between nucleoid-associated proteins HU and Lsr2 of *Mycobacterium tuberculosis*: altered DNA binding and gene regulation. *Mol Microbiol* 111:981–994. <https://doi.org/10.1111/mmi.14202>.
35. Alqaseer K, Turapov O, Barthe P, Jagatia H, De Visch A, Roumestand C, Wegrzyn M, Bartek IL, Voskuil MI, O'Hare HM, Ajuh P, Bottrill AR, Witney AA, Cohen-Gonsaud M, Waddell SJ, Mukamolova GV. 2019. Protein kinase B controls *Mycobacterium tuberculosis* growth via phosphorylation of the transcriptional regulator Lsr2 at threonine 112. *Mol Microbiol* 112:1847–1862. <https://doi.org/10.1111/mmi.14398>.
36. Dilweg IW, Dame RT. 2018. Post-translational modification of nucleoid-associated proteins: an extra layer of functional modulation in bacteria? *Biochem Soc Trans* 46:1381–1392. <https://doi.org/10.1042/BST20180488>.
37. Kieser T, Bibb MJ. 2004. Practical *Streptomyces* genetics. John Innes Centre, Norwich, England.
38. Gust B, Challis GL, Fowler K, Kieser T, Chater KF. 2003. PCR-targeted *Streptomyces* gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin. *Proc Natl Acad Sci U S A* 100:1541–1546. <https://doi.org/10.1073/pnas.0337542100>.
39. MacNeil DJ, Gewain KM, Ruby CL, Dezeny G, Gibbons PH, MacNeil T. 1992. Analysis of *Streptomyces avermitilis* genes required for avermectin biosynthesis utilizing a novel integration vector. *Gene* 111:61–68. [https://doi.org/10.1016/0378-1119\(92\)90603-m](https://doi.org/10.1016/0378-1119(92)90603-m).
40. Paget MS, Chamberlin L, Atrih A, Foster SJ, Buttner MJ. 1999. Evidence that the extracytoplasmic function sigma factor sigmaE is required for normal cell wall structure in *Streptomyces coelicolor* A3(2). *J Bacteriol* 181:204–211. <https://doi.org/10.1128/JB.181.1.204-211.1999>.
41. Cannavo E, Johnson D, Andres SN, Kissling VM, Reinert JK, Garcia V, Erie DA, Hess D, Thoma NH, Enchev RI, Peter M, Williams RS, Neale MJ, Cejka P. 2018. Regulatory control of DNA end resection by Sae2 phosphorylation. *Nat Commun* 9:4016. <https://doi.org/10.1038/s41467-018-06417-5>.
42. Andres SN, Li ZM, Erie DA, Williams RS. 2019. Ctp1 protein-DNA filaments promote DNA bridging and DNA double-strand break repair. *J Biol Chem* 294:3312–3320. <https://doi.org/10.1074/jbc.RA118.006759>.
43. Li Z. 2019. Developing new AFM imaging technique and software for DNA mismatch repair. PhD thesis. University of North Carolina, Chapel Hill, NC.
44. Bush MJ, Bibb MJ, Chandra G, Findlay KC, Buttner MJ. 2013. Genes required for aerial growth, cell division, and chromosome segregation are targets of WhiA before sporulation in *Streptomyces venezuelae*. *mBio* 4:e00684-13. <https://doi.org/10.1128/mBio.00684-13>.
45. Peirson SN, Butler JN, Foster RG. 2003. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. *Nucleic Acids Res* 31:e73. <https://doi.org/10.1093/nar/gng073>.
46. St-Onge RJ, Haiser HJ, Yousef MR, Sherwood E, Tschowri N, Al-Bassam M, Elliot MA. 2015. Nucleotide second messenger-mediated regulation of a marulytic enzyme in *Streptomyces*. *Mol Microbiol* 96:779–795. <https://doi.org/10.1111/mmi.12971>.
47. Myronovskiy M, Welle E, Fedorenko V, Luzhetskyy A. 2011. Beta-glucuronidase as a sensitive and versatile reporter in actinomycetes. *Appl Environ Microbiol* 77:5370–5383. <https://doi.org/10.1128/AEM.00434-11>.
48. Hanahan D. 1985. Techniques for transformation of *E. coli*, p 109–135. In Glover DM (ed), *DNA cloning: a practical approach*, vol 1. IRL Press, Washington, DC.
49. Gregory MA, Till R, Smith MC. 2003. Integration site for *Streptomyces* phage phiBT1 and development of site-specific integrating vectors. *J Bacteriol* 185:5320–5323. <https://doi.org/10.1128/JB.185.17.5320-5323.2003>.